While researchers are still struggling to understand the mechanisms causing the wide ranging symptoms of chronic fatigue syndrome (CFS), it seems clear that impaired immune system function and/or some sort of mitochondrial dysfunction is involved. Supporting mitochondrial function and reducing damaging free radicals that are produced by excess electrons via direct supplementation with ubiquinol can help support energy production and reduce symptoms of fatigue, as shown in a recent double-blinded, placebo-controlled study.
Forty-three patients with CFS were randomly assigned to receive either ubiquinol (150 mg/day) or placebo, with results showing that supplementation with ubiquinol for 12 weeks is effective for improving several CFS symptoms, including improved sleep and decreases in fatigue levels and depression levels, that were directly correlated to increased levels of plasma ubiquinol. As adequate plasma levels may be important for inducing antifatigue effects, ensuring optimal bioavailability is vital for successful interventions. Not only is ubiquinol superior to ubiquinone in terms of uptake, but enhancing bioavailability using a suitable carrier such as VESIsorb, will further enhance plasma levels, ensuring optimal therapeutic outcomes.
Our rapid-action VESIsorb® Ubiquinol-QH is the most advanced Coenzyme Q10 (CoQ10) supplement available. Its fast-track patented VESIsorb®delivery system ‘pre-digests’ ubiquinol for unprecedented absorption, higher blood plasma levels and up to 6x longer-lasting action.